Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Treatment-Resistant PTSD
NCT05243329Phase 2Unknown
- Sponsor
- Halucenex Life Sciences
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in post-traumatic stress disorder (PTSD), sponsored by Halucenex Life Sciences. Status: unknown.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05243329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243329.